Literature DB >> 9877136

Congenital muscular dystrophy with merosin deficiency: MRI findings in five patients.

L Farina1, L Morandi, I Milanesi, E Ciceri, M Mora, I Moroni, C Pantaleoni, M Savoiardo.   

Abstract

We present the MRI findings in five patients with congenital muscular dystrophy (CMD) and merosin (laminin alpha2) deficiency, which was total in one and partial in four. In one patient with partial merosin deficiency, MRI was normal. The other four patients had supratentorial white matter abnormalities. In three, T2-weighted images revealed subcortical, deep lobar and periventricular high signal in white matter, while in the other there were only small peritrigonal areas of increased signal. On T1-weighted images, there was slightly low signal. Cortical abnormalities were absent. None of these changes were accompanied by symptoms or signs of central nervous system involvement. White matter abnormalities in a patient with CMD should prompt investigation of merosin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9877136     DOI: 10.1007/s002340050689

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  8 in total

Review 1.  Glia unglued: how signals from the extracellular matrix regulate the development of myelinating glia.

Authors:  Holly Colognato; Iva D Tzvetanova
Journal:  Dev Neurobiol       Date:  2011-11       Impact factor: 3.964

Review 2.  The expanding phenotype of laminin alpha2 chain (merosin) abnormalities: case series and review.

Authors:  K J Jones; G Morgan; H Johnston; V Tobias; R A Ouvrier; I Wilkinson; K N North
Journal:  J Med Genet       Date:  2001-10       Impact factor: 6.318

3.  Analysis and classification of cerebellar malformations.

Authors:  Sandeep Patel; A James Barkovich
Journal:  AJNR Am J Neuroradiol       Date:  2002-08       Impact factor: 3.825

4.  Merosin-deficient congenital muscular dystrophy (CMD): a study of 25 Brazilian patients using MRI.

Authors:  Claudia C Leite; Leandro T Lucato; Maria G M Martin; Lucio G Ferreira; Maria B D Resende; Mary S Carvalho; Suely K N Marie; J Randy Jinkins; Umbertina C Reed
Journal:  Pediatr Radiol       Date:  2005-03-05

5.  Beta1 integrins are required for normal CNS myelination and promote AKT-dependent myelin outgrowth.

Authors:  Claudia S Barros; Tom Nguyen; Kathryn S R Spencer; Akiko Nishiyama; Holly Colognato; Ulrich Müller
Journal:  Development       Date:  2009-08       Impact factor: 6.868

Review 6.  Consensus statement on standard of care for congenital muscular dystrophies.

Authors:  Ching H Wang; Carsten G Bonnemann; Anne Rutkowski; Thomas Sejersen; Jonathan Bellini; Vanessa Battista; Julaine M Florence; Ulrike Schara; Pamela M Schuler; Karim Wahbi; Annie Aloysius; Robert O Bash; Christophe Béroud; Enrico Bertini; Kate Bushby; Ronald D Cohn; Anne M Connolly; Nicolas Deconinck; Isabelle Desguerre; Michelle Eagle; Brigitte Estournet-Mathiaud; Ana Ferreiro; Albert Fujak; Nathalie Goemans; Susan T Iannaccone; Patricia Jouinot; Marion Main; Paola Melacini; Wolfgang Mueller-Felber; Francesco Muntoni; Leslie L Nelson; Jes Rahbek; Susana Quijano-Roy; Caroline Sewry; Kari Storhaug; Anita Simonds; Brian Tseng; Jiri Vajsar; Andrea Vianello; Reinhard Zeller
Journal:  J Child Neurol       Date:  2010-11-15       Impact factor: 1.987

7.  Limb girdle muscular dystrophy due to LAMA2 gene mutations: new mutations expand the clinical spectrum of a still challenging diagnosis.

Authors:  Francesca Magri; Roberta Brusa; Luca Bello; Lorenzo Peverelli; Roberto Del Bo; Alessandra Govoni; Claudia Cinnante; Irene Colombo; Francesco Fortunato; Roberto Tironi; Stefania Corti; Nadia Grimoldi; Monica Sciacco; Nereo Bresolin; Elena Pegoraro; Maurizio Moggio; Giacomo Pietro Comi
Journal:  Acta Myol       Date:  2020-06-01

8.  Integrin-linked kinase is required for laminin-2-induced oligodendrocyte cell spreading and CNS myelination.

Authors:  Soo Jin Chun; Matthew N Rasband; Richard L Sidman; Amyn A Habib; Timothy Vartanian
Journal:  J Cell Biol       Date:  2003-10-27       Impact factor: 10.539

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.